Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Gains from Sales and Divestitures (2023 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $922848.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Sales and Divestitures rose 538.31% to $922848.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $922848.0, a 538.31% increase, with the full-year FY2024 number at $416368.0, up 415.37% from a year prior.
  • Gains from Sales and Divestitures was $922848.0 for Q3 2025 at Orchestra BioMed Holdings, up from $625414.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $922848.0 in Q3 2025 to a low of $13100.0 in Q1 2024.
  • A 3-year average of $253482.5 and a median of $112683.5 in 2023 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: plummeted 64.85% in 2024, then soared 2704.3% in 2025.
  • Orchestra BioMed Holdings' Gains from Sales and Divestitures stood at $80790.0 in 2023, then surged by 415.37% to $416368.0 in 2024, then soared by 121.64% to $922848.0 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Gains from Sales and Divestitures are $922848.0 (Q3 2025), $625414.0 (Q2 2025), and $178286.0 (Q1 2025).